Lyle Ostrow MD PhD

Please join us on February 12th at 4PM ET for Dr. Ernest Fraenkel's Distinguished Lecture - "What's a useful definition of a disease? Approaches for target discovery and patient stratification." temple.zoom.us/j/99060976097 @TempleResearch @TempleUniv @TempleHealth

#BetterTogether #EndALS

@youralsnetwork, in partnership with ALS United, will accept Letters of Intent for ALS research funding from March 16 – April 20, 2026. As part of our ALS Research Innovation Initiative, we invite bold, imaginative proposals that push the field forward and accelerate progress toward better treatments and cures. Apply for funding at researchfunding.alsnetwork.org starting March 16. For questions about the process or the ALS Research Innovation Initiative, email research@alsnetwork.org.

New funding opportunity from #youralsnetwork. Check it out, and write good proposals! #EndALS #BetterTogether

QurAlis is pleased to announce interim data from its ANQUR clinical trial which demonstrated QRL-201 had an effect on disease progression in #ALS patients; this effect was confirmed by markers of clinical efficacy and changes in a clinically relevant biomarker, along with target engagement. These data support an open-label extended dosing period to the ANQUR clinical trial protocol under which all eligible trial participants will be given the opportunity to receive QRL-201 at the low dose of the dose-range finding portion of the study. The open-label extended dosing period to the ANQUR clinical trial has been approved in Canada and is currently under regulatory review in the European Union and the United Kingdom. In parallel, QurAlis is preparing to advance QRL-201 into a pivotal Phase 3 clinical trial in 2027. QRL-201 is a first-in-class, potent antisense oligonucleotide (#ASO) #precisionmedicine in development to restore STATHMIN-2 (STMN2) expression in ALS patients with the aim to modify disease progression and improve outcomes. ANQUR (QRL-201-01; NCT05633459) is the first-ever clinical trial to evaluate a potential therapy to rescue STMN2 expression in people living with ALS. #neurodegenerativediseases #neurologicaldiseases bit.ly/3OwZMCz

Use code 447 this tax season and help those who are battling neurodegenerative diseases like ALS. Contribute to the California ALS Research Network Voluntary Tax Contribution Fund. At least $250,000 must be raised annually for the program to remain on the CA income tax return form. Make an impact on ALS research today by contributing $1 or more. There is no maximum contribution amount! Please share this opportunity far and wide! Learn more at: alsnetwork.org/taxfund.

Join on zoom! Today at 4PM ET. temple.zoom.us/j/99060976097

Please join us on February 12th at 4PM ET for Dr. Ernest Fraenkel's Distinguished Lecture - "What's a useful definition of a disease? Approaches for target discovery and patient stratification." temple.zoom.us/j/99060976097 @TempleResearch @TempleUniv @TempleHealth

Starts in 30 mins! Not only is Dr. Pattee a phenomenal neuromuscular clinician and scientist, he was my dad's medical student at UT Houston in the early 1980s! #BetterTogether #EndALS

@PatrickMoranTB Not that it matters, but extrapolating Thomas' total over a 17-game season would be 1,580 yards. Cook needs 166 yards over final 3 games to beat that. He still should do it as long as he plays all 3 games.

With three games left, James Cook is within 72 yards of Thurman Thomas's single-season, career-best 1,487 rushing yards in 1992. Cook's going to end up with more rushing yards than any Bill ever not named OJ Simpson. Just a little perspective on how special he's been this year.

I missed part of the AM session of the @mndassoc #alsmndsymp to watch the game with my parents, but I was there in spirit! Not shown: I'm also wearing my @ALSHF polo shirt and @everything_als jacket! #GoBills #BILLSMAFIA4LIFE #BetterTogether #EndALS #EndMND @TempleNeurology

Great meeting. Lots of work to do. #BetterTogether #EndALS #NEALS2025 #NEALSMtg

The #LongitudePrizeOnALS is a project around AI-based approaches to transform drug discovery for the treatment of ALS/MND. Delivered by Challenge Works & funded by the MND Association with FightMND + other funders. Applications close 3 Dec '25 15:00 GMT:als.longitudeprize.org

#BetterTogether #EndALS

📢 Big news for @TempleNeurology Residency-- this year we are expanding our program and will recruit 1 advanced position in addition to our 6 categorical spots! Keep an eye out for our open house announcement soon - looking forward to meeting everyone! #neurotwitter #match2026

People living with ALS: ALS research counts on you! When you join the Registry, you can complete risk factor surveys that will help researchers better understand ALS. Join today: bit.ly/2MVxoYZ

AI can now create a cloned voice that sounds almost indistinguishable from your natural voice. Your simulated voice can then be used on a text-to-speech app or communication device. Learn more at youralsguide.com/voice-banking #ALS

Every year, we invite experts to give talks at the International Symposium on #ALS/#MND. This year is no different! We are thrilled to have 22 plenary speakers covering #ALS #MND research and clinical management. Find out more ⬇️ symposium.mndassociation.org/programme/plen… #alsmndsymp

Here is my take on the tree of life / neuron / DNA. I made it out of Sapele wood. The base is ash. #sciart

Listener effort measures clinically meaningful change of dysarthria in amyotrophic lateral sclerosis. #BetterTogether #EndALS #OpenScience @everything_als @ALSHF @TempleNeurology academic.oup.com/braincomms/art…

@EvaFeldmanMDPhD His talk was phenomenal, as always!

I was sorry to miss ENCALS this year, but Dr. Stephen Goutman gave a keynote on "Epidemiology and Epigenetics: Bridging Genes, Environment, and Disease."